Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04697472
Other study ID # DOC1622
Secondary ID Pro00046320
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2021
Est. completion date September 13, 2022

Study information

Verified date September 2022
Source ONWARD Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) administered by the LIFT System to treat upper extremity functional deficits in people with chronic tetraplegia.


Description:

The primary endpoint of this pivotal study will report device related safety and changes in established metrics of upper extremity performance after treatment with the study device. To ensure that the benefits realized in the study are directly attributable to the ARC Therapy, all enrolled subjects will first undergo a guided, in-clinic conventional functional task practice (FTP) program lasting approximately two months to regain their upper extremity (UE) function. Performance gains realized during this wash-in period provide a subject specific control that reflects the limits of conventional functional task practice without stimulation (standard of care). At the conclusion of the wash-in period, subjects will complete pre-stimulation testing of UE function. To test the additive benefit of training with stimulation, combined functional task practice and ARC Therapy will then be administered over a period of approximately two months using the LIFT System. Functional task practice will follow established rehabilitation protocols that are specific to the individual subject's specific needs and capabilities (Beekhuizen & Field-Fote, Functional Task Practice versus Functional Task Practice with Stimulation: Effects on Upper Extremity Function and Cortical Plasticity in Individuals with Incomplete Cervical Spinal Cord Injury, 2005). Training will be graded to accommodate performance improvement over time, thus maximizing the potential benefit to subjects. Subjects will participate in up to 20 in-clinic training sessions per month. At the end of training period, the improvement in UE function will be measured and used to assess the progress of primary study endpoints. The choice of primary outcome measures for this pivotal study is dictated by the following factors - 1. Safety, 2. Relevance to UE function, 3. Capture improvements in performance, and 4. Magnitude of changes that are clinically meaningful. All performance metrics will be assessed at enrollment, at the completion of the wash-in period and at the end of the ARC Therapy assessment period. Subjects with clinically meaningful gains in multiple performance domains resulting from the ARC Therapy with LIFT will be considered responders. Additionally, gains during the wash-in (control) period will be compared to gains during the ARC Therapy with LIFT (test) period. Safety will be evaluated throughout the entire study through periodic monitoring and analysis of all reported adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date September 13, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 22 Years to 75 Years
Eligibility Key Inclusion Criteria: Subjects must meet all the following criteria: 1. At least 22 years old and no older than 75 years old at the time of enrollment 2. Non-progressive cervical spinal cord injury from C2-C8 inclusive 3. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification B, C, or D 4. Indicated for upper extremity training procedures by subject's treating physician or a physical therapist 5. Minimum 12 months post-injury 6. Capable of providing informed consent Key Exclusion Criteria: Subjects must not meet any of the following criteria: 1. Has uncontrolled cardiopulmonary disease or cardiac symptoms as determined by the Investigator 2. Has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations like severe neuropathic pain, depression, mood disorders or other cognitive disorders 3. Has been diagnosed with autonomic dysreflexia that is severe, unstable, and uncontrolled 4. Requires ventilator support 5. Has an autoimmune etiology of spinal cord dysfunction/injury 6. Spasms that limit the ability of the subjects to participate in the study training as determined by the Investigator 7. Breakdown in skin area that will come into contact with electrodes 8. Has any active implanted medical device 9. Pregnant, planning to become pregnant or currently breastfeeding 10. Concurrent participation in another drug or device trial that may interfere with this study 11. In the opinion of the investigators, the study is not safe or appropriate for the participant

Study Design


Intervention

Device:
LIFT System
The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.

Locations

Country Name City State
Canada KITE Research Institute /University Health Network Toronto Ontario
Canada International Collaboration on Repair Discoveries (ICORD), University of British Columbia Vancouver British Columbia
Netherlands Reade, Centre for Rehabilitation and Rheumatology Amsterdam Noord-Holland
Netherlands Sint Maartenskliniek, Department of Rehabilitation Nijmegen Gelderland
United Kingdom Queen Elizabeth National Spinal Injuries Unit Glasgow
United States Shepherd Center- Crawford Research Institute Atlanta Georgia
United States James J. Peters VA Medical Center Bronx New York
United States INSPIRE Laboratory, Spaulding Hospital Cambridge Massachusetts
United States Craig Hospital Englewood Colorado
United States Miller School of Medicine, The Miami Project to Cure Paralysis Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Thomas Jefferson University/Magee Rehabilitation Hospitals Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States University of Washington Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
ONWARD Medical, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Netherlands,  United Kingdom, 

References & Publications (2)

Hoffman L, Field-Fote E. Effects of practice combined with somatosensory or motor stimulation on hand function in persons with spinal cord injury. Top Spinal Cord Inj Rehabil. 2013 Fall;19(4):288-99. doi: 10.1310/sci1904-288. — View Citation

Inanici F, Samejima S, Gad P, Edgerton VR, Hofstetter CP, Moritz CT. Transcutaneous Electrical Spinal Stimulation Promotes Long-Term Recovery of Upper Extremity Function in Chronic Tetraplegia. IEEE Trans Neural Syst Rehabil Eng. 2018 Jun;26(6):1272-1278. doi: 10.1109/TNSRE.2018.2834339. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of serious adverse events (SAEs) Safety demonstrated through observational data regarding the incidence of serious adverse events (SAEs) related to the use of the study device and treatment procedures will be reported. Through completion of the study, an average of 16 months
Primary Number of participants with change in upper extremity strength and function Change in upper extremity strength and function performance metrics after treatment with ARC Therapy administered by the LIFT System and Functional Task Practice (FTP) is assessed using ISNCSCI, GRASSP,CUE-T, pinch/grasp forces.
The primary effectiveness outcome measure will test the hypothesis that a majority of the subjects will experience clinically significant improvement in UE performance metrics (defined as therapy responders) after treatment with ARC Therapy administered by the LIFT System and Functional Task Practice (FTP).
Through completion of the study, an average of 16 months
Secondary Superiority of combined FTP and ARC Therapy with LIFT vs. FTP alone. Superiority as demonstrated by statistically significant difference in the proportion of subjects reporting improvement between the two treatment groups. Through completion of the study, an average of 16 months
See also
  Status Clinical Trial Phase
Completed NCT04074616 - Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation N/A
Completed NCT00816803 - Cell Transplant in Spinal Cord Injury Patients Phase 1/Phase 2
Completed NCT05284201 - LIFT Home Study of Non-Invasive ARC Therapy for Spinal Cord Injury N/A
Completed NCT03458871 - Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation N/A
Active, not recruiting NCT02136823 - Impact of Persistent Conductances on Motor Unit Firing in SCI N/A
Completed NCT03989440 - AXER-204 in Participants With Chronic Spinal Cord Injury Phase 1/Phase 2
Recruiting NCT05644171 - RESTORES Trial: RESToration Of Rehabilitative Function With Epidural Spinal Stimulation N/A
Recruiting NCT05965700 - NVG-291 in Spinal Cord Injury Subjects Phase 1/Phase 2